The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin Lymphoma
Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
Clinical Pearls
Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma. This trial, labeled DYNAMO, was presented at the 2014 ASCO Annual Meeting.
- In the course of a phase I investigation of IPI-145, patients with indolent lymphoma were enrolled.
- The overall response rate of this group was 73%. The complete response rate was 20%.
- These results were compelling enough to enroll a single-arm study of 120 patients with refractory indolent non-Hodgkin lymphoma. The trial is ongoing.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
